Clinical Research Directory
Browse clinical research sites, groups, and studies.
Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy
Sponsor: Mahidol University
Summary
A study comparing efficacy of olanzapine versus placebo to prevent nausea and vomiting from moderate emetic risk chemotherapy
Official title: A Prospective Randomized, Double-blind Controlled Trial of Olanzapine Versus Placebo in Addition to Ondansetron Plus Dexamethasone As Antiemetic Prophylaxis in Patients Receiving Moderately Emetogenic Chemotherapy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
140
Start Date
2025-01-10
Completion Date
2026-01-31
Last Updated
2025-02-27
Healthy Volunteers
No
Conditions
Interventions
olanzapine
olanzapine 5 mg oral prior to chemotherapy on day 1 and daily on day 2-4
Placebo
placebo 5 mg oral prior to chemotherapy on day 1 and daily on day 2-4
Locations (1)
Faculty of Medicine Siriraj Hospital, Mahidol University
Bangkok, Bangkok, Thailand